BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33867349)

  • 1. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations.
    Li W; Wu H; Xu X; Zhang Y
    Aging (Albany NY); 2021 Apr; 13(8):11564-11594. PubMed ID: 33867349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
    Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
    Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline Duplication of SNORA18L5 Increases Risk for HBV-related Hepatocellular Carcinoma by Altering Localization of Ribosomal Proteins and Decreasing Levels of p53.
    Cao P; Yang A; Wang R; Xia X; Zhai Y; Li Y; Yang F; Cui Y; Xie W; Liu Y; Liu T; Jia W; Jiang Z; Li Z; Han Y; Gao C; Song Q; Xie B; Zhang L; Zhang H; Zhang J; Shen X; Yuan Y; Yu F; Wang Y; Xu J; Ma Y; Mo Z; Yu W; He F; Zhou G
    Gastroenterology; 2018 Aug; 155(2):542-556. PubMed ID: 29702115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma.
    Xu LX; He MH; Dai ZH; Yu J; Wang JG; Li XC; Jiang BB; Ke ZF; Su TH; Peng ZW; Guo Y; Chen ZB; Chen SL; Peng S; Kuang M
    Ann Oncol; 2019 Jun; 30(6):990-997. PubMed ID: 30916311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
    Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
    J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma.
    Chan AW; Zhang Z; Chong CC; Tin EK; Chow C; Wong N
    J Pathol; 2019 Oct; 249(2):166-172. PubMed ID: 31168847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disparity of Hepatocellular Carcinoma in Tumor Microenvironment-Related Genes and Infiltrating Immune Cells between Asian and Non-Asian Populations.
    Huang LH; Hsieh TM; Huang CY; Liu YW; Wu SC; Chien PC; Hsieh CH
    Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
    Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
    Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-exome sequencing-based mutational profiling of hepatocellular adenoma malignant transformation to hepatocellular carcinoma.
    Bu Y; Huang R; Gao J; Qu W; Fu X; Liu W; Ding Z; Zhou J; Fan J; Wang X; Chen D; Tang Z
    Clin Exp Pharmacol Physiol; 2024 Jul; 51(7):e13901. PubMed ID: 38843867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.
    Huang FY; Wong DK; Tsui VW; Seto WK; Mak LY; Cheung TT; Lai KK; Yuen MF
    BMC Cancer; 2019 Aug; 19(1):789. PubMed ID: 31395065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of molecular heterogeneity of hepatocellular carcinoma based on immune gene expression signatures.
    Lou X; Wang JJ; Wei YQ; He YJ; Jiang ZJ; Sun JJ
    Med Oncol; 2021 Mar; 38(5):50. PubMed ID: 33786682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of LRP1B mutation-associated prognostic model for hepatocellular carcinoma.
    Xu J; Shen X; Zhang B; Su R; Cui M; Yan L; Cao Y
    Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34386813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence.
    Zhou SL; Zhou ZJ; Hu ZQ; Song CL; Luo YJ; Luo CB; Xin HY; Yang XR; Shi YH; Wang Z; Huang XW; Cao Y; Fan J; Zhou J
    J Hepatol; 2019 Dec; 71(6):1152-1163. PubMed ID: 31349001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic structures of dysplastic nodule and concurrent hepatocellular carcinoma.
    Lee M; Kim K; Kim SY; Jung SH; Yoon J; Kim MS; Park HC; Jung ES; Chung YJ; Lee SH
    Hum Pathol; 2018 Nov; 81():37-46. PubMed ID: 29949741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyroptosis related genes signature predicts prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma.
    Fang G; Zhang Q; Fan J; Li H; Ding Z; Fu J; Wu Y; Zeng Y; Liu J
    BMC Cancer; 2022 Sep; 22(1):999. PubMed ID: 36127654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma.
    Bassaganyas L; Pinyol R; Esteban-Fabró R; Torrens L; Torrecilla S; Willoughby CE; Franch-Expósito S; Vila-Casadesús M; Salaverria I; Montal R; Mazzaferro V; Camps J; Sia D; Llovet JM
    Clin Cancer Res; 2020 Dec; 26(23):6350-6361. PubMed ID: 32873569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
    Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
    Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
    Ye S; Zhao XY; Hu XG; Li T; Xu QR; Yang HM; Huang DS; Yang L
    Oncol Rep; 2017 Apr; 37(4):2215-2226. PubMed ID: 28350084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B-related hepatocellular carcinoma: classification and prognostic model based on programmed cell death genes.
    Tian J; Meng J; Yang Z; Song L; Jiang X; Zou J
    Front Immunol; 2024; 15():1411161. PubMed ID: 38799437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.